. 2. Venook AP Niedzwiecki D Lenz HJ . CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon
Search Results
Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini
5-FU and capecitabine-based chemoradiation. Four randomized trials examined the effects of adding oxaliplatin to 5-FU or capecitabine-based preoperative chemoradiation. 11 , 13 – 16 Three of these (NSABP R-04, 11 STAR-01, 13 and ACCORD 12 14
Margaret A. O'Grady, Elena Gitelson, Ramona F. Swaby, Lori J. Goldstein, Elaine Sein, Patricia Keeley, Bonnie Miller, Tianyu Li, Alan Weinstein, and Steven J. Cohen
. Cornfeld MJ Jadwin A O'Grady P . Feasibility of assessing quality in medical oncology practices . Cancer Pract 2001 ; 9 : 231 – 235 . 8. Andre T Boni C Mounedji-Boudiaf L . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for
/15/14 Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin Expiration Date: 3/15/14
Expiration Date: 3/15/14 NCCN Guidelines® Insights: Non-Hodgkin's Lymphomas, Version 1.2013 Expiration Date: 3/15/14 Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin Expiration Date: 3/15/14 CASE REPORT: A Patient With
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
Characteristics Median duration of AC was 3.63 months (IQR, 2.7) ( Figure 2 ). Of the patients who received AC, 42.2% were treated with multiagent chemotherapy: 60.8% received 5-FU/oxaliplatin (FOLFOX), 26.7% received capecitabine/oxaliplatin (CAPEOX), and 12
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski
represent a continuum of care and that these lines of treatment are blurred rather than discrete. 24 For example, if oxaliplatin is administered as a part of an initial treatment regimen but is discontinued after 12 weeks or earlier for escalating
David M. Dunning and Thomas A. Paivanas
: results from the National Surgical Adjuvant Breast and Bowel Project B-15 . J Clin Oncol 1990 ; 8 : 1483 – 1496 . 17. De Gramont A Banzi M Navarro M . Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized
Tanios Bekaii-Saab
) present in 16% of tumors previously identified as KRAS (exon 2 codons 12/13) wild-type may allow for further refinement. A predefined retrospective analysis of the large prospective randomized trial PRIME (FOLFOX4 [leucovorin, 5-FU, and oxaliplatin
Kim Margolin
/II study of sequential high dose VIP plus paclitaxel in patients with poor prognosis germ cell tumor (Abstr #691) . Proc Am Soc Clin Oncol 2001 ; 20 : 173a . 19 Soulie P Garrino C Bensmaine MA . Antitumoral activity of oxaliplatin
